Burkholderia Infections - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Burkholderia Infections - Pipeline Review, H1 2016

Burkholderia Infections - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Burkholderia Infections - Pipeline Review, H1 2016
Published Jun 22, 2016
76 pages — Published Jun 22, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Burkholderia Infections - Pipeline Review, H1 2016, provides an overview of the Burkholderia Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burkholderia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkholderia Infections and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Burkholderia Infections
- The report reviews pipeline therapeutics for Burkholderia Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Burkholderia Infections therapeutics and enlists all their major and minor projects
- The report assesses Burkholderia Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Burkholderia Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Burkholderia Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding

  
Source:
Document ID
GMDHC8190IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Burkholderia Infections Overview81
Therapeutics Development92
  Pipeline Products for Burkholderia Infections Overview91
  Pipeline Products for Burkholderia Infections Comparative Analysis101
Burkholderia Infections Therapeutics under Development by Companies111
Burkholderia Infections Therapeutics under Investigation by Universities/Institutes121
Burkholderia Infections Pipeline Products Glance133
  Clinical Stage Products131
  Early Stage Products141
  Unknown Stage Products151
Burkholderia Infections Products under Development by Companies161
Burkholderia Infections Products under Investigation by Universities/Institutes171
Burkholderia Infections Companies Involved in Therapeutics Development1811
  Arno Therapeutics, Inc.181
  Bavarian Nordic A/S191
  Emergent BioSolutions Inc.201
  Eumedica SA211
  Grifols, S.A.221
  NanoBio Corporation231
  Sarepta Therapeutics, Inc.241
  Soligenix, Inc.251
  Syntiron LLC261
  TGV-Laboratories271
  Vault Pharma Inc.281
Burkholderia Infections Therapeutics Assessment299
  Assessment by Monotherapy Products291
  Assessment by Target302
  Assessment by Mechanism of Action322
  Assessment by Route of Administration342
  Assessment by Molecule Type362
Drug Profiles3830
  Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections Drug Profile381
  Antisense RNAi Oligonucleotide to Inhibit Nucleoporin p62 for Burkholderia Infections Drug Profile391
  AR-13 Drug Profile401
  ARD-3100 Drug Profile414
  ARD-3150 Drug Profile455
  Burkholderia pseudomallei vaccine Drug Profile501
  Burkholderia vaccine Drug Profile511
  Burkholderia vaccine Drug Profile521
  dusquetide Drug Profile534
  EV-035 Drug Profile572
  GC-072 Drug Profile591
  melioidosis vaccine Drug Profile601
  Mul-1867 Drug Profile611
  NB-401 Drug Profile621
  SGX-101 Drug Profile631
  SGX-943 Drug Profile641
  Small Molecules to Inhibit InhA for Infectious Diseases Drug Profile651
  temocillin Drug Profile661
  VPI-231 Drug Profile671
Burkholderia Infections Dormant Projects681
Burkholderia Infections Discontinued Products691
Burkholderia Infections Product Development Milestones705
  Featured News &Press Releases701
    May 31, 2016: FDA Grants Soligenix Fast Track Designation for SGX943 for the Treatment of Melioidosis701
    Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC701
    Aug 14, 2014: US DTRA to fund preclinical work on Evolva s antibiotic GC-072711
    Feb 21, 2014: Bavarian Nordic s MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development711
    Feb 21, 2014: Bavarian Nordic s MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development711
    Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis721
    Sep 10, 2012: Evolva Presents Preclinical Data On EV-035 At ICAAC721
    Oct 15, 2009: NanoBio s Nanoemulsion Kills Drug-Resistant Bacteria Found In Cystic Fibrosis Patients732
Appendix752
  Methodology751
  Coverage751
  Secondary Research751
  Primary Research751
  Expert Panel Validation751
  Contact Us751
  Disclaimer761

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Burkholderia Infections - Pipeline Review, H1 2016" Jun 22, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Burkholderia-Infections-Pipeline-Review-H1-2016-2088-15983>
  
APA:
Global Markets Direct - Market Research. (2016). Burkholderia Infections - Pipeline Review, H1 2016 Jun 22, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Burkholderia-Infections-Pipeline-Review-H1-2016-2088-15983>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.